U.S. markets close in 4 hours 21 minutes
  • S&P 500

    4,534.26
    +14.63 (+0.32%)
     
  • Dow 30

    35,590.64
    +133.33 (+0.38%)
     
  • Nasdaq

    15,138.83
    +9.74 (+0.06%)
     
  • Russell 2000

    2,289.54
    +13.63 (+0.60%)
     
  • Crude Oil

    83.39
    +0.43 (+0.52%)
     
  • Gold

    1,784.80
    +14.30 (+0.81%)
     
  • Silver

    24.30
    +0.42 (+1.75%)
     
  • EUR/USD

    1.1650
    +0.0012 (+0.10%)
     
  • 10-Yr Bond

    1.6440
    +0.0090 (+0.55%)
     
  • GBP/USD

    1.3818
    +0.0025 (+0.18%)
     
  • USD/JPY

    114.2100
    -0.1500 (-0.13%)
     
  • BTC-USD

    66,751.17
    +4,119.91 (+6.58%)
     
  • CMC Crypto 200

    1,547.06
    +66.25 (+4.47%)
     
  • FTSE 100

    7,227.02
    +9.49 (+0.13%)
     
  • Nikkei 225

    29,255.55
    +40.03 (+0.14%)
     

LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

LEXINGTON, Mass., July 8, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood, today announced that Frederic Chereau, chief executive officer of LogicBio, will participate in a virtual panel discussion entitled "Delivery and Durability of Genetic Medicines" at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, 2021 at 10:00 a.m. ET.

About LogicBio Therapeutics
LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. The Company's first platform, GeneRide™, is a new approach to precise gene insertion harnessing a cell's natural DNA repair process potentially leading to durable therapeutic protein expression levels. The Company's second platform, sAAVy™, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a broad range of indications and tissues. The Company is based in Lexington, MA. For more information, visit www.logicbio.com, which does not form a part of this release.

Investor Contact:
Laurence Watts
Gilmartin Group
(619) 916-7620
laurence@gilmartinir.com

Media Contacts:
Adam Daley
Berry & Company Public Relations
W: 212-253-8881
C: 614-580-2048
adaley@berrypr.com

Jenna Urban
Berry & Company Public Relations
W: 212-253-8881
C: 203-218-9180
jurban@berrypr.com

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/logicbio-therapeutics-to-participate-in-william-blair-biotech-focus-conference-2021-301327648.html

SOURCE LogicBio Therapeutics, Inc.